Fundraising Fox
ENDRA Life Sciences
NASDAQ: NDRAAnn Arbor, US · Delaware corporation
Find your way into ENDRA Life Sciences
168 people in our graph can introduce you to the ENDRA Life Sciences team.
Sign up to see every warm intro you have to ENDRA Life Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ENDRA Life Sciences team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ENDRA develops Thermo-Acoustic Enhanced UltraSound (TAEUS) technology, an ultrasound-based device for assessing and monitoring liver fat to help diagnose conditions such as NAFLD and NASH at the point of care. The technology is also aimed at other applications including visualizing tissue temperature during energy-based surgery and detecting arterial plaque or internal bleeding.
Founders & leadership
MT
Michael ThorntonExecutive
RJ
Richard JacrouxExecutive
FR
Francois R. MichelonExecutiveFrancois Michelon has held leadership roles across imaging, surgical, and implantable device companies, including building an AI-driven biomarker imaging company through its Nasdaq IPO and CE marking while expanding its patent portfolio, and reversing a sales decline at a PE-backed dental technology business. He currently serves as Executive Officer and Director at ENDRA Life Sciences.
DW
David WellsExecutive
Board
AD
Anthony DiGiandomenicoBoard director
LJ
Louis J. BaseneseBoard director
MH
Michael HarshBoard director
AT
Alexander TokmanBoard director
SS
Sanjiv S. GambhirBoard director
Reported raises · per SEC filings
Form D private placements$26.8M disclosed across 4 rounds · 2018–2025
▶$14.4MraisedOct 2025 · 6 investors · BiotechnologyRule 506(c)
▶$14.4MraisedOct 2025 · 6 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Michael ThorntonExecutive Officer
- Richard JacrouxExecutive Officer
- Louis J. BaseneseDirector
- Anthony DiGiandomenicoDirector
- Michael HarshDirector
- Alexander TokmanExecutive Officer, Director
- Offering amount
- $14.4M
- Amount sold
- $14.4M
- Minimum investment
- $200K
- Sales commissions
- $295.5K
- Placement agents
- Lucid Capital Markets, LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$8.6MraisedDec 2019 · 151 investors · BiotechnologyRule 506(b)
▶$8.6MraisedDec 2019 · 151 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander TokmanDirector
- Michael HarshDirector
- Anthony DiGiandomenicoDirector
- Sanjiv S. GambhirDirector
- David WellsExecutive Officer
- Michael ThorntonExecutive Officer
- Francois R. MichelonExecutive Officer, Director
- Offering amount
- $8.6M
- Amount sold
- $8.6M
- Minimum investment
- $5K
- Sales commissions
- $766.2K
- Placement agents
- Newbridge Securities Corporation
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedJul 2019 · 86 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJul 2019 · 86 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HarshDirector
- David WellsExecutive Officer
- Francois R. MichelonExecutive Officer, Director
- Michael ThorntonExecutive Officer
- Alexander Y. TokmanDirector
- Sanjiv S. GambhirDirector
- Anthony DiGiandomenicoDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- Minimum investment
- $20K
- Sales commissions
- $280.5K
- Placement agents
- National Securities Corporation
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJul 2018 · 18 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJul 2018 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Francois R. MichelonExecutive Officer, Director
- Michael HarshDirector
- Sanjiv S. GambhirDirector
- David WellsExecutive Officer
- Michael ThorntonExecutive Officer
- Anthony DiGiandomenicoDirector
- Alexander Y. TokmanDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- Sales commissions
- $107.7K
- Placement agents
- National Securities Corporation
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ENDRA Life Sciences do?
- ENDRA develops Thermo-Acoustic Enhanced UltraSound (TAEUS) technology, an ultrasound-based device for assessing and monitoring liver fat to help diagnose conditions such as NAFLD and NASH at the point of care. The technology is also aimed at other applications including visualizing tissue temperature during energy-based surgery and detecting arterial plaque or internal bleeding.
- How much funding has ENDRA Life Sciences raised?
- ENDRA Life Sciences has disclosed $26.8M raised across 4 rounds.
- Where is ENDRA Life Sciences headquartered?
- ENDRA Life Sciences is headquartered in Ann Arbor, US.